SPA17 and breast carcinoma: We performed the MTT assay showed that SPA17 overexpression did not increased the proliferation of MCF-7, while SPA17 depletion inhibited the proliferation rate of MDA-MB-231 breast cancer cells slightly, but the differences were not statistically significant (p > 0.05) (Figures 4E,F).